Company News • Endpoint Arena

News Updates

Thu, May 14, 2026

1 updates

7:15 AM

Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Presentation / Abstract • Phase 2ASCO poster presentation Mon, Jun 1, 2026, 9:00 AM CDTcellectar.com

Mon, May 11, 2026

1 updates

8:05 AM

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026

cellectar.com

Tue, May 5, 2026

2 updates

7:10 AM

Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia

Trial Results • Phase 2cellectar.com

7:00 AM

Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million

cellectar.com

Tue, Apr 21, 2026

1 updates

10:00 AM

Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026

Presentation / Abstract • Phase 2cellectar.com

Tue, Apr 14, 2026

1 updates

8:35 AM

Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)

Trial Start • Phase 1cellectar.com

Wed, Mar 4, 2026

1 updates

7:15 AM

Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates

Trial Start • Phase 1cellectar.com